1832 Asset Management
APLS

1832 Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

1832 Asset Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-661,700
Closed -$60.3M – 855
2023
Q2 		$60.3M Buy
661,700
+530,800
+406% +$45.8M 0.07% 163
2023
Q1 		$8.63M Buy
+130,900
New +$7.55M 0.01% 366
2022
Q4 		– Sell
-88,100
Closed -$6.02M – 893
2022
Q3 		$6.02M Buy
+88,100
New +$5.21M 0.01% 412

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

1832 Asset Management's APLS Position: Q3 2023 in Review

1832 Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q3 2023, closing a stake of 661,700 shares — an estimated $60.3M sold.

1832 Asset Management first reported a position in APLS in Q3 2022 and held it in 3 quarters. The position peaked at $60.3M in Q2 2023. 256 funds tracked by Wall St. Rank hold APLS as of Q3 2023.

  • 1832 Asset Management reported no remaining Apellis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • 1832 Asset Management sold 661,700 Apellis Pharmaceuticals shares in Q3 2023, an estimated $60.3M.
  • 1832 Asset Management first reported a position in Apellis Pharmaceuticals in Q3 2022 and held it in 3 quarters.
  • 1832 Asset Management's Apellis Pharmaceuticals position peaked at $60.3M in Q2 2023.
  • 256 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2023.

Based on 1832 Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.